https://www.selleckchem.com/products/gdc-0068.html
BACKGROUND Despite the growing concern about the safety of gadolinium-based contrast agents (GBCAs), they are still the most commonly used. Ferumoxytol, as an off-label alternative MRI contrast agent, cannot be administered by a rapid bolus for dynamic susceptibility contrast perfusion-weighted imaging (DSC-PWI). PURPOSE To assess the feasibility of iron sucrose (IS) as a contrast agent for MR angiography (MRA) and DSC-PWI. STUDY TYPE Prospective animal model. ANIMAL MODEL Thirty-six normal rats (16 for MRA, 20 for biocompability tests
Like
Comment
Share
